X0306 4 2020-04-15 0 0001636050 Axovant Gene Therapies Ltd. AXGT 0001745995 Corcoran Gavin C/O AXOVANT GENE THERAPIES LTD. 11 TIMES SQUARE, 33RD FLOOR NEW YORK NY 10036 0 1 0 0 EVP of R&D Stock Option (Right to Buy) 3.45 2020-04-15 4 A 0 63700 0.00 A 2030-04-14 Common Shares 63700 63700 D Restricted Stock Units 2020-04-15 4 A 0 42400 0.00 A Common Shares 42400 42400 D The option vests over a period of four years with 25% of the common shares underlying the option vesting on April 15, 2021 and the remainder vesting in 12 equal quarterly installments thereafter, subject to Reporting Person providing continuous service to the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan Each restricted stock unit represents the right to receive one share of the Issuer's common stock. One-third of the common shares underlying the restricted stock unit shall vest on April 15, 2021, April 15, 2022 and April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date. /s/ Alison Haggerty, Attorney-In-Fact 2020-04-17